Revive Therapeutics Ltd. Logo

Revive Therapeutics Ltd.

RVVTF

(1.8)
Stock Price

0,01 USD

-297.65% ROA

-68.39% ROE

-0.75x PER

Market Cap.

2.930.201,87 USD

0.63% DER

0% Yield

0% NPM

Revive Therapeutics Ltd. Stock Analysis

Revive Therapeutics Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Revive Therapeutics Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.98x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (3%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

5 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

6 ROE

Negative ROE (-30.99%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-236.73%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Revive Therapeutics Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Revive Therapeutics Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Revive Therapeutics Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Revive Therapeutics Ltd. Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Revive Therapeutics Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2013 64.231
2014 164.644 60.99%
2015 747.559 77.98%
2016 1.568.288 52.33%
2017 408.216 -284.18%
2018 373.192 -9.38%
2019 124.808 -199.01%
2020 455.089 72.58%
2021 6.704.623 93.21%
2022 4.973.116 -34.82%
2022 15.155.893 67.19%
2023 533.540 -2740.63%
2023 3.583.225 85.11%
2024 1.887.848 -89.8%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Revive Therapeutics Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 127.256
2014 739.292 82.79%
2015 1.261.759 41.41%
2016 1.123.094 -12.35%
2017 1.261.968 11%
2018 1.468.184 14.05%
2019 1.191.977 -23.17%
2020 3.200.270 62.75%
2021 11.611.896 72.44%
2022 1.155.428 -904.99%
2022 2.668.340 56.7%
2023 1.010.648 -164.02%
2023 1.459.735 30.76%
2024 5.004.676 70.83%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Revive Therapeutics Ltd. EBITDA
Year EBITDA Growth
2013 -191.486
2014 -555.131 65.51%
2015 -1.994.126 72.16%
2016 -2.650.007 24.75%
2017 -1.729.861 -53.19%
2018 -1.893.304 8.63%
2019 -1.313.300 -44.16%
2020 -4.813.006 72.71%
2021 -18.494.945 73.98%
2022 -6.052.544 -205.57%
2022 -17.716.225 65.84%
2023 -1.532.240 -1056.23%
2023 -5.411.969 71.69%
2024 -7.422.200 27.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Revive Therapeutics Ltd. Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 0 0%
2016 -6.224 100%
2017 -3.572 -74.24%
2018 -3.132 -14.05%
2019 -3.201 2.16%
2020 -28.265 88.68%
2021 -775 -3547.1%
2022 0 0%
2022 -578 100%
2023 0 0%
2023 -434 100%
2024 -328 -32.32%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Revive Therapeutics Ltd. Net Profit
Year Net Profit Growth
2013 -193.391
2014 -1.257.089 84.62%
2015 -2.031.102 38.11%
2016 -2.737.932 25.82%
2017 -1.615.900 -69.44%
2018 -1.790.848 9.77%
2019 -1.343.886 -33.26%
2020 -5.381.687 75.03%
2021 -20.118.802 73.25%
2022 -6.099.784 -229.83%
2022 -17.806.927 65.74%
2023 -1.562.492 -1039.65%
2023 -6.320.900 75.28%
2024 -7.487.824 15.58%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Revive Therapeutics Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Revive Therapeutics Ltd. Free Cashflow
Year Free Cashflow Growth
2013 -156.156
2014 -800.277 80.49%
2015 -1.531.293 47.74%
2016 -1.988.052 22.98%
2017 -2.082.739 4.55%
2018 -1.509.329 -37.99%
2019 -1.185.603 -27.3%
2020 -2.515.584 52.87%
2021 -11.306.839 77.75%
2022 -13.060.490 13.43%
2022 -876.306 -1390.4%
2023 -495.528 -76.84%
2023 -6.025.722 91.78%
2024 -1.635.554 -268.42%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Revive Therapeutics Ltd. Operating Cashflow
Year Operating Cashflow Growth
2013 -156.156
2014 -768.463 79.68%
2015 -1.493.292 48.54%
2016 -1.986.552 24.83%
2017 -2.081.224 4.55%
2018 -1.498.426 -38.89%
2019 -1.184.918 -26.46%
2020 -2.515.584 52.9%
2021 -8.306.839 69.72%
2022 -13.060.490 36.4%
2022 -876.306 -1390.4%
2023 -495.528 -76.84%
2023 -6.025.722 91.78%
2024 -1.635.554 -268.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Revive Therapeutics Ltd. Capital Expenditure
Year Capital Expenditure Growth
2013 0
2014 31.814 100%
2015 38.001 16.28%
2016 1.500 -2433.4%
2017 1.515 0.99%
2018 10.903 86.1%
2019 685 -1491.68%
2020 0 0%
2021 3.000.000 100%
2022 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Revive Therapeutics Ltd. Equity
Year Equity Growth
2013 89.832
2014 1.265.040 92.9%
2015 2.361.989 46.44%
2016 568.637 -315.38%
2017 1.615.192 64.79%
2018 821.117 -96.71%
2019 960.782 14.54%
2020 7.429.029 87.07%
2021 28.806.723 74.21%
2022 12.602.716 -128.58%
2022 9.513.654 -32.47%
2023 10.261.990 7.29%
2023 10.652.613 3.67%
2024 9.817.394 -8.51%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Revive Therapeutics Ltd. Assets
Year Assets Growth
2013 753.725
2014 1.342.816 43.87%
2015 2.666.426 49.64%
2016 1.387.067 -92.23%
2017 1.923.694 27.9%
2018 1.120.417 -71.69%
2019 1.282.554 12.64%
2020 8.260.580 84.47%
2021 29.806.400 72.29%
2022 17.065.297 -74.66%
2022 13.845.091 -23.26%
2023 13.780.441 -0.47%
2023 14.251.705 3.31%
2024 13.142.712 -8.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Revive Therapeutics Ltd. Liabilities
Year Liabilities Growth
2013 10.168
2014 77.776 86.93%
2015 304.437 74.45%
2016 818.430 62.8%
2017 308.502 -165.29%
2018 299.300 -3.07%
2019 321.772 6.98%
2020 831.551 61.3%
2021 999.677 16.82%
2022 4.462.581 77.6%
2022 4.331.437 -3.03%
2023 3.518.451 -23.11%
2023 3.599.092 2.24%
2024 3.325.318 -8.23%

Revive Therapeutics Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-0.75x
Price To Sales Ratio
0x
POCF Ratio
-0.89
PFCF Ratio
-0.82
Price to Book Ratio
0.32
EV to Sales
0
EV Over EBITDA
-0.56
EV to Operating CashFlow
-0.53
EV to FreeCashFlow
-0.53
Earnings Yield
-1.33
FreeCashFlow Yield
-1.22
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.08
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.85
ROE
-0.42
Return On Assets
-0.57
Return On Capital Employed
-0.42
Net Income per EBT
1
EBT Per Ebit
1.98
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.34
Return on Tangible Assets
-2.98
Days Sales Outstanding
0
Days Payables Outstanding
2614704.75
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
1563876651982.4
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,03
Tangible Book Value per Share
-0
Shareholders Equity per Share
0.03
Interest Debt per Share
0
Debt to Equity
0.01
Debt to Assets
0
Net Debt to EBITDA
0.31
Current Ratio
0.4
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
9771189
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.89
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Revive Therapeutics Ltd. Dividends
Year Dividends Growth

Revive Therapeutics Ltd. Profile

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

CEO
Mr. Michael Frank
Employee
3
Address
The Canadian Venture Building
Toronto, M5C 1P1

Revive Therapeutics Ltd. Executives & BODs

Revive Therapeutics Ltd. Executives & BODs
# Name Age
1 Dr. Onesmo Mpanju Ph.D.
Chief Regulatory Affairs Consultant
70
2 Dr. Kelly T. McKee Jr., M.D., M.P.H.
Chief Scientific Officer Consultant
70
3 Mr. Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPA
Chief Financial Officer
70
4 Mr. Michael Frank
Chairman & Chief Executive Officer
70

Revive Therapeutics Ltd. Competitors